Medinol v. Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Manhattan federal court judge Alvin Hellerstein sets June 20 trial date to hear Medinol's breach-of-contract claims against Boston Scientific, relating to Taxus and Express stents (1"The Gray Sheet" Dec. 6, 2004, In Brief). Medinol, which is seeking royalties, developed and manufactured stents for Boston Scientific from 1995-2000 until the relationship soured. Medinol claims Boston Scientific conducted a secret project - called "Project Independence" - under which it shifted its manufacturing and R&D programs in-house...
You may also be interested in...
Boston Scientific v. Medinol
Manhattan federal court rules Medinol is entitled to try its claims that Boston Scientific's sales of Taxus and Express stents are a breach of contract, entitling it to royalties, the Israeli firm states Dec. 2. A status conference is slated for Jan. 13 to set a trial date. Medinol developed and manufactured stents for Boston Scientific beginning in 1995 until the relationship soured in 2000, when Boston Scientific revealed a secret project - called "Project Independence" - under which it shifted its manufacturing and R&D programs in-house by building a plant in Galway, Ireland (1"The Gray Sheet" April 8, 2002, p. 14). Boston Scientific says the court's ruling will not interfere with Taxus paclitaxel-eluting stent sales. In a Dutch court, Medinol recently sought a 30% royalty from Boston Scientific on all past and future sales of Taxus in and from The Netherlands (2"The Gray Sheet" Feb. 16, 2004, p. 20)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.